
## RAW SEQUENCE LISTING ERROR REPORT



The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following CRF diskette:

Application Serial Number: 09/(21,0/7)Art Unit / Team No.: 1644

Date Processed by STIC:

THE ATTACHED PRINTOUT EXPLAINS THE ERRORS DETECTED.

PLEASE BE SURE TO FORWARD THIS INFORMATION TO THE APPLICANTS BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANTS ALONG WITH A NOTICE TO COMPLY or,
- 2) CALLING APPLICANTS AND FAXING THEM A COPY OF THE PRINTOUT WITH A NOTICE TO COMPLY

THIS WILL INSURE THAT THE NEXT SUBMISSION RECEIVED FROM THEM WILL BE ERROR FREE.

IF YOU HAVE ANY FURTHER QUESTIONS, PLEASE CALL:

**MARK SPENCER 703-308-4212** 

## Raw Sequence Listing Error Summary

			10/010
	ERROR DETECTED	SUGGESTED CORRECTION	SERIAL NUMBER: <u>09//2/, 01</u> /
TN.	NEW RULES CASES: PI	LEASE DISREGARD ENGLISH "ALPHA" HEADERS, W	HICH WERE INSERTED BY PTO SOFTWARE
••••	Wrapped Nucleics	The number/text at the end of each line "wrapped" down	to the next line.
_	Wapped Walles	This may occur if your file was retrieved in a word proces	sor after creating it.
		Please adjust your right margin to .3, as this will prevent	
	Wrapped Aminos	The amino acid number/text at the end of each line "wrap	oped " down to the next line.
	**************************************	This may occur if your file was retrieved in a word proces	ssor after creating it.
		Please adjust your right margin to .3, as this will prevent	
		· · · · · · · · · · · · · · · · · · ·	•
	Incorrect Line Length	The rules require that a line not exceed 72 characters in	length. This includes spaces.
_	mooneet Emo Eonge.		
	Misaligned Amino Acid	The numbering under each 5th amino acid is misaligned.	This may be caused by the use of tabs
_	Numbering	between the numbering. It is recommended to delete any	tabs and use spacing between the numbers.
	Hambering		
	Non-ASCII	This file was not saved in ASCII (DOS) text, as required	by the Sequence Rules.
	Non-Addin	Please ensure your subsequent submission is saved in A	ASCII text so that it can be processed.
		, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
	Variable Length	Sequence(s) contain n's or Xaa's which represente	d more than one residue.
	Valiable Lengar	As per the rules, each n or Xaa can only represent a sing	gle residue.
		Please present the maximum number of each residue ha	ving variable length and
		indicate in the (ix) feature section that some may be mis	
	Patentin ver. 2.0 "bug"	A "bug" in PatentIn version 2.0 has caused the <220>-<2	223> section to be missing from amino acid
_		sequence(s) Normally, Patentin would a	automatically generate this section from the
		previously coded nucleic acid sequence. Please manua	ally copy the relevant <220>-<223> section
		to the subsequent amino acid sequence.	
		•	
	Skipped Sequences	Sequence(s) missing. If intentional, please use the	following format for each skipped sequence:
	(OLD RULES)	(2) INFORMATION FOR SEQ ID NO:X:	•
	•	(i) SEQUENCE CHARACTERISTICS:(Do not insert any	headings under "SEQUENCE CHARACTERISTICS")
		(xi) SEQUENCE DESCRIPTION:SEQ ID NO:X:	
		This sequence is intentionally skipped	
		Please also adjust the "(iii) NUMBER OF SEQUENCES:	response to include the skipped sequence(s).
_	Skipped Sequences	Sequence(s) missing. If intentional, please use the	following format for each skipped sequence.
	(NEW RULES)	<210> sequence id number	
		<400> sequence id number	
		000	
_	Use of n's or Xaa's	Use of n's and/or Xaa's have been detected in the Seque	
	(NEW RULES)	Use of <220> to <223> is MANDATORY if n's or Xaa's a	re present.
		In <220> to <223> section, please explain location of n of	or Xaa, and which residue n or Xaa represents.
	Use of <213>Organism	Sequence(s) are missing this mandatory field o	r its response.
	(NEW RULES)	135 (maybe more)	
		7 20 (may	and the diame
<u>_</u>	Use of <220>Feature	Sequence(s) (are missing the <2207 earth and as	SOCIATED READINGS.
	(NEW RULES)	Use of <220> to <223> is MANDATORY if <213>ORGAI	
		Please explain source of genetic material in <220> to	
		(See "Federal Register," 6/01/98, Vol. 63, No.	104, pp. 29631-32) (Sec. 1.823 of new Rules)
	Patentin ver. 2.0 "bug"	Please do not use "Copy t Disk" function of Patenti	n version 2.0. This causes a corrupted
		file, resulting in missing mandatory numeric identifiers ar	nd responses (as indicated on raw sequence listing).
		Instead, please use "File Manager" or any other means t	to copy file to floppy disk.
	•	AKS-Biotechnology Systems Branch- 5/1:	2/99

1644

PAGE:

RAW SEQUENCE LISTING

DATE: 12/17/1999

PATENT APPLICATION US/09/121,017

TIME: 16:20:58

Input Set: I121017.RAW

This Raw Listing contains the General Information Section and up to first 5 pages.

Does Not Comply Corrected Diskette Needed

```
<110> APPLICANT: Imamura, Toru
           Asada, Masahiro
           Oka, Syuichi
 3
 4
           Suzuki, Masashi
 5
           Yoneda, Atsuko
 6
          Ota, Keiko
 7
           Oda, Yuko
          Miyakawa, Kazuko
 8
 9
           Orikasa, Noriko
10
          Asada, Chie
          Kojima, Tetsuhito
11
     <120> TITLE OF INVENTION: HEPARIN-BINDING PROTEINS MODIFIED WITH SUGAR CHAINS,
12
           METHOD OF PRODUCING THE SAME AND PHARMACEUTICAL
13
           COMPOSITIONS CONTAINING THE SAME
14
     <130> FILE REFERENCE: PH-559US
     <140> CURRENT APPLICATION NUMBER: US/09/121,017
16
     <141> CURRENT FILING DATE: 1998-07-23
17
     <150> EARLIER APPLICATION NUMBER: 307721/1997
18
    <151> EARLIER FILING DATE: 1997-11-10
19
     <160> NUMBER OF SEQ ID NOS: 30
20
21
    <170> SOFTWARE: PatentIn Ver. 2.0
22
     <210> SEQ ID NO 1
23
     <211> LENGTH: 221
                                           Sel Jen 12 on Eva Summary
Sheet
     <212> TYPE: PRT
24
25
     <213> ORGANISM: Artificial Sequence
26
     <400> SEOUENCE: 1
           Met Ala Pro Ala Arg Leu Phe Ala Leu Leu Phe Phe Val Gly Gly
27
28
                                                10
           Val Ala Glu Ser Ile Arg Glu Thr Glu Val Ile Asp Pro Gln Asp Leu
29
30
           Leu Glu Gly Arg Tyr Phe Ser Gly Ala Leu Pro Asp Asp Glu Asp Val
31
32
                                        40
           Val Gly Pro Gly Gln Glu Ser Asp Asp Phe Glu Leu Ser Gly Ser Gly
33
34
                                    55
           Asp Leu Asp Asp Leu Glu Asp Ser Met Ile Gly Pro Glu Val Val His
35
36
                                70
           Pro Leu Val Pro Leu Asp Ala Asn Tyr Lys Lys Pro Lys Leu Leu Tyr
37
38
                                                90
39
          Cys Ser Asn Gly Gly His Phe Leu Arg Ile Leu Pro Asp Gly Thr Val
40
                                           105
          Asp Gly Thr Arg Asp Arg Ser Asp Gln His Ile Gln Leu Gln Leu Ser
41
42
                                       120
43
          Ala Glu Ser Val Gly Glu Val Tyr Ile Lys Ser Thr Glu Thr Gly Gln
44
              130
                                   135
                                                       140
```

DATE: 12/17/1999 TIME: 16:20:58 PAGE: 2 RAW SEQUENCE LISTING

PATENT APPLICATION US/09/121,017

45		Tyr	Leu	Ala	Met	Asp	Thr	Asp	Gly	Leu	Leu	Tyr	Gly	Ser	Gln	Thr	Pro	
46		145					150					155					160	
47		Asn	Glu	Glu	Cys	Leu	Phe	Leu	Glu	Arg		Glu	Glu	Asn	His	_	Asn	
48						165					170					175		
49		Thr	Tyr	Ile		Lys	Lys	His	Ala	Glu	Lys	Asn	Trp	Phe	Val	Gly	Leu	
50					180					185					190	_		
51		Lys	Lys	Asn	Gly	Ser	Cys	Lys	Arg	Gly	Pro	Arg	Thr	His	Tyr	Gly	Gln	
52				195					200					205				
53		Lys		Ile	Leu	Phe	Leu	Pro	Leu	Pro	Val	Ser	Ser	Asp				
54			210					215					220				•	
55	<210>	SEQ	ID I	NO 2														
56	<211>	LEN	GTH:	663														
57	<212>	TYP	E: DI	AV														
58	<213>	ORG	ANISI	M: A:	rtif	icia:	l Sec	quen	ce									
59	<220>										•							
60	<223>	OTH	ER II	VFOR	ITAN	ON: I	Desci	ript:	ion (	of A	rtif:	icia:	l Sec	quen	ce: 1	Eusi	on of	
61		seq	ience	e for	r a j	part	of l	humai	n ry	docai	n and	daj	part	of l	humaı	n fil	brobla	st
62		grov	wth :	Eacto	or 1													
63	<220>	FEA:	TURE	:														
64	<221>																	
65	<222>	LOC	OITA	<b>1</b> : (:	1)	(663)	)											
66	<400>	SEQ	JENC	E: 2														•
67		_	_		_	cgt	_			_	_	_			_			48
68		Met	Ala	Pro	Ala	Arg	Leu	Phe	Ala	Leu	Leu	Leu	Phe	Phe	Val	Gly	Gly	
69		1				5					10					15		
70		gtc	gcc	gag	tcg	atc	cga	gag	act	gag	gtc	atc	gac	CCC	cag	gac	ctc	96
71		Val	Ala	Glu	Ser	Ile	Arg	Glu	Thr	Glu	Val	Ile	Asp	Pro	Gln	Asp	Leu	
72					20					25					30			
73			_		_	tac				-			_	_		_	_	144
74		Leu	Glu	Gly	Arg	Tyr	Phe	Ser	Gly	Ala	Leu	Pro	Asp	Asp	Glu	Asp	Val	
75				35					40					45				
76		-				cag	_		_	-			_					192
77		Val	Gly	Pro	Gly	Gln	Glu	Ser	Asp	Asp	Phe	Glu	Leu	Ser	Gly	Ser	Gly	
78			50					55					60					
79		_	_	-	-	ttg	-	_						_	_	_		240
80		Asp	Leu	Asp	Asp	Leu	Glu	Asp	Ser	Met	Ile	Gly	Pro	Glu	Val	Val	His	
81		65				•	70					75					80	
82			_			cta	_	-			_	_						288
83		Pro	Leu	Val	Pro	Leu	Asp	Ala	Asn	Tyr	Lys	Lys	Pro	Lys	Leu	Leu	Tyr	
84						85					90					95		
85		-	_			ggc			_				_	_				336
86		Cys	Ser	Asn	Gly	Gly	His	Phe	Leu	Arg	Ile	Leu	Pro	Asp	Gly	Thr	Val	
87					100					105					110			
88		_				gac							_	_	_		_	384
89		Asp	Gly	Thr	Arg	Asp	Arg	Ser		Gln	His	Ile	Gln	Leu	Gln	Leu	Ser	
90				115					120					125				
91			_	_		ggg					_	_					_	432
92		Ala	Glu	Ser	Val	Gly	Glu	Val	Tyr	Ile	Lys	Ser	Thr	Glu	Thr	Gly	Gln	
93			130					135					140					
94		tac	ttg	gcc	atg	gac	acc	gac	ggg	ctt	tta	tac	ggc	tca	cag	aca	cca	480

TIME: 16:20:58

PAGE: 3 RAW SEQUENCE LISTING DATE: 12/17/1999

PATENT APPLICATION US/09/121,017

```
Tyr Leu Ala Met Asp Thr Asp Gly Leu Leu Tyr Gly Ser Gln Thr Pro
 95
 96
                              150
            aat gag gaa tgt ttg ttc ctg gaa agg ctg gag gag aac cat tac aac
                                                                                528
 97
            Asn Glu Glu Cys Leu Phe Leu Glu Arg Leu Glu Glu Asn His Tyr Asn
 98
                                                 170
                            165
 99
            acc tat ata tcc aag aag cat gca gag aag aat tgg ttt gtt ggc ctc
                                                                                576
100
101
            Thr Tyr Ile Ser Lys Lys His Ala Glu Lys Asn Trp Phe Val Gly Leu
102
                        180
                                             185
103
            aag aag aat ggg agc tgc aaa cgc ggt cct cgg act cac tat ggc cag
            Lys Lys Asn Gly Ser Cys Lys Arg Gly Pro Arg Thr His Tyr Gly Gln
104
                                        200
105
106
            aaa gca atc ttg ttt ctc ccc ctg cca gtc tct tct gat
                                                                                663
            Lys Ala Ile Leu Phe Leu Pro Leu Pro Val Ser Ser Asp
107
108
                210
                                    215
                                                         220
      <210> SEQ ID NO 3
109
110
      <211> LENGTH: 175
      <212> TYPE: PRT
111
      <213> ORGANISM: Artificial Sequence
112
      <400> SEQUENCE: 3
113
            Met Ser Arg Gly Ala Gly Arg Val Gln Gly Thr Leu Gln Ala Leu Val
114
115
            Phe Leu Gly Val Leu Val Gly Met Val Val Pro Ser Pro Ala Gly Ala
116
                                             25
117
                         20
            Arg Ala Asn Gly Thr Leu Leu Asp Ala Asn Tyr Lys Lys Pro Lys Leu
118
119
                                         40
120
            Leu Tyr Cys Ser Asn Gly Gly His Phe Leu Arg Ile Leu Pro Asp Gly
121
                                     55
                                                          60
            Thr Val Asp Gly Thr Arg Asp Arg Ser Asp Gln His Ile Gln Leu Gln
122
                                                      75
123
            Leu Ser Ala Glu Ser Val Gly Glu Val Tyr Ile Lys Ser Thr Glu Thr
124
125
                             85
                                                  90
            Gly Gln Tyr Leu Ala Met Asp Thr Asp Gly Leu Leu Tyr Gly Ser Gln
126
127
                        100
                                            105
128
            Thr Pro Asn Glu Glu Cys Leu Phe Leu Glu Arg Leu Glu Glu Asn His
                                        120
129
            Tyr Asn Thr Tyr Ile Ser Lys Lys His Ala Glu Lys Asn Trp Phe Val
130
131
                                    135
            Gly Leu Lys Lys Asn Gly Ser Cys Lys Arg Gly Pro Arg Thr His Tyr
132
133
                                150
                                                     155
            Gly Gln Lys Ala Ile Leu Phe Leu Pro Leu Pro Val Ser Ser Asp
134
135
                            165
                                                 170
                                                                     175
      <210> SEQ ID NO 4
136
137
      <211> LENGTH: 525
138
      <212> TYPE: DNA
      <213> ORGANISM: Artificial Sequence
139
      <220> FEATURE:
140
      <223> OTHER INFORMATION: Description of Artificial Sequence: fusion of
141
            sequence for a part of mouse fibroblast growth factor 6 and
142
143
            a part of human fibroblast growth factor 1
      <220> FEATURE:
```

PAGE: 4 RAW SEQUENCE LISTING DATE: 12/17/1999

PATENT APPLICATION US/09/121,017 TIME: 16:20:58

```
<221> NAME/KEY: CDS
145
      <222> LOCATION: (1)..(525)
146
      <400> SEQUENCE: 4
147
            atg tee egg gga gea gga egt gtt eag gge aeg etg eag get ete gte
148
                                                                                48
            Met Ser Arg Gly Ala Gly Arg Val Gln Gly Thr Leu Gln Ala Leu Val
149
150
151
            ttc tta ggc gtc cta gtg ggc atg gtg gtg ccc tca cct gcc ggc gcc
            Phe Leu Gly Val Leu Val Gly Met Val Val Pro Ser Pro Ala Gly Ala
152
153
                                              25
          . cgc gcc aac ggc acg cta ctg gac gct aat tac aag aag ccc aaa ctc
154
155
            Arg Ala Asn Gly Thr Leu Leu Asp Ala Asn Tyr Lys Lys Pro Lys Leu
156
                     35
                                          40
            ctc tac tgt agc aac ggg ggc cac ttc ctg agg atc ctt ccg gat ggc
157
                                                                                192
158
            Leu Tyr Cys Ser Asn Gly Gly His Phe Leu Arg Ile Leu Pro Asp Gly
159
                                     55
                                                          60
160
            aca gtg gat ggg aca agg gac agg agc cag cac att cag ctg cag
            Thr Val Asp Gly Thr Arg Asp Arg Ser Asp Gln His Ile Gln Leu Gln
161
162
                                 70
            ctc agt gcg gaa agc gtg ggg gag gtg tat ata aag agt acc gag act
                                                                                288
163
            Leu Ser Ala Glu Ser Val Gly Glu Val Tyr Ile Lys Ser Thr Glu Thr
                                                  90
165
                             85
            ggc cag tac ttg gcc atg gac acc gac ggg ctt tta tac ggc tca cag
166
                                                                                336
167
            Gly Gln Tyr Leu Ala Met Asp Thr Asp Gly Leu Leu Tyr Gly Ser Gln
168
                                             105
            aca cca aat gag gaa tgt ttg ttc ctg gaa agg ctg gag gag aac cat
169
                                                                                384
170
            Thr Pro Asn Glu Glu Cys Leu Phe Leu Glu Arg Leu Glu Glu Asn His
171
                                         120
172
            tac aac acc tat ata tcc aag aag cat gca gag aag aat tgg ttt gtt
                                                                                432
            Tyr Asn Thr Tyr Ile Ser Lys Lys His Ala Glu Lys Asn Trp Phe Val
173
174
                130
                                    135
            gge etc aag aag aat ggg age tge aaa ege ggt eet egg aet eac tat
175
                                                                                480
176
            Gly Leu Lys Lys Asn Gly Ser Cys Lys Arg Gly Pro Arg Thr His Tyr
177
                                150
                                                     155
                                                                          160
178
            ggc cag aaa gca atc ttg ttt ctc ccc ctg cca gtc tct tct gat
                                                                                525
179
            Gly Gln Lys Ala Ile Leu Phe Leu Pro Leu Pro Val Ser Ser Asp
                                                 170
180
                                                                      175
                            165
181
      <210> SEQ ID NO 5
      <211> LENGTH: 181
182
183
      <212> TYPE: PRT
      <213> ORGANISM: Artificial Sequence
184
      <400> SEQUENCE: 5
185
            Met Ser Arg Gly Ala Gly Arg Val Gln Gly Thr Leu Gln Ala Leu Val
186
187
            Phe Leu Gly Val Leu Val Gly Met Val Val Pro Ser Pro Ala Gly Ala
188
189
                         20
                                             25
            Arg Ala Gln Gly Thr Leu Leu Asp Ala Asn Tyr Lys Lys Pro Lys Leu
190
191
                                         40
            Leu Tyr Cys Ser Asn Gly Gly His Phe Leu Arg Ile Leu Pro Asp Gly
192
193
                                     55
            Thr Val Asp Gly Thr Arg Asp Arg Ser Asp Gln His Ile Gln Leu Gln
```

DATE: 12/17/1999 TIME: 16:20:58 PAGE: 5 RAW SEQUENCE LISTING

PATENT APPLICATION US/09/121,017

195 65 70 75 80  196 Leu Ser Ala Glu Ser Val Gly Glu Val Tyr Ile Lys Ser Thr Glu Thr 197 85 90 95  198 Gly Gln Tyr Leu Ala Met Asp Thr Asp Gly Leu Leu Tyr Gly Ser Gln 199 100 105 110  200 Thr Pro Asn Glu Glu Cys Leu Phe Leu Glu Arg Leu Glu Glu Ala Ala 201 115 120 125  202 Thr Pro Ala Pro Asn His Tyr Asn Thr Tyr Ile Ser Lys Lys His Ala 203 130 135 140  204 Glu Lys Asn Trp Phe Val Gly Leu Lys Lys Asn Gly Ser Cys Lys Arg 205 145 150 155 160  206 Gly Pro Arg Thr His Tyr Gly Gln Lys Ala Ile Leu Phe Leu Pro Leu 207 165 170 175  208 Pro Val Ser Ser Asp 209 180  210 <210> SEQ ID NO 6
197 198 Gly Gln Tyr Leu Ala Met Asp Thr Asp Gly Leu Leu Tyr Gly Ser Gln 199 100 100 105 110 200 Thr Pro Asn Glu Glu Cys Leu Phe Leu Glu Arg Leu Glu Glu Ala Ala 201 202 Thr Pro Ala Pro Asn His Tyr Asn Thr Tyr Ile Ser Lys Lys His Ala 203 130 130 135 140 204 Glu Lys Asn Trp Phe Val Gly Leu Lys Lys Asn Gly Ser Cys Lys Arg 205 145 150 150 155 160 206 Gly Pro Arg Thr His Tyr Gly Gln Lys Ala Ile Leu Phe Leu Pro Leu 207 165 170 175 208 Pro Val Ser Ser Asp 209 180 <a href="mailto:separates"><a href="mailto:separates"></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a></a>

PAGE: 6

VERIFICATION SUMMARY DATE: 12/17/1999
PATENT APPLICATION US/09/121,017 TIME: 16:20:58 VERIFICATION SUMMARY

Input Set: I121017.RAW

Line ? Error/Warning

Original Text